Epidemology of Acute Kidney Injury in Diabetic Patients Infected With covid_19 In Assiut University Hospital
1 other identifier
observational
100
1 country
1
Brief Summary
The novel coronavirus SARS-CoV-2 was identified as the causative agent for a series of atypical respiratory diseases in Wuhan, China in December of 2019(.1) The disease termed COVID-19, was officially declared a pandemic by the World Health Organization on March 11, 2020. SARS-CoV-2 contains a single-stranded, positive-sense RNA genome surrounded by an extracellular membrane containing a series of spike glycoproteins resembling a crown.COVID-19 infection results in diverse symptoms and morbidity depending on individual genetics, ethnicity, age, and geographic location. In severe cases, COVID-19 pathophysiology includes destruction of lung epithelial cells, thrombosis, hypercoagulation, and vascular leak leading to sepsis.(2) COVID-19 risk factors include cardiovascular disease, hypertension, and diabetes.(2)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 1, 2021
CompletedStudy Start
First participant enrolled
October 1, 2021
CompletedFirst Posted
Study publicly available on registry
October 12, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 20, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 20, 2022
CompletedOctober 12, 2021
October 1, 2021
5 months
October 1, 2021
October 9, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
percentage of AKI in covid_19 in diabetic pt
diabetic pt with AKI due to infection with covid \_19
6 months
Study Arms (3)
covid not diabetic with AKI
AKI in pt with covid\_19 not diabetic
AKI in covid_19 in diabetic
AKI in covid\_19 in diabetic pt
covid_19 in diabetic
covid\_19 in diabetic without AKI
Interventions
laboratory data
Eligibility Criteria
The Data will be collected by a questionnaire includes the followings: * Socio demographic data (name, age, sex, Body weight and height, job, marital status, number of children, educational level and residence etc). * Main presenting symptoms * History of hypertension, chronic kidney disease, ect.
You may qualify if:
- patients admitted because of COVID-19 infetion.
You may not qualify if:
- Patients with ESRD on regular dialysis ,Patients with stage 4 or 5 non-dialysis if the condition proven to be progression of the already known diagnosis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Doaa Ramadan Rezk
Asyut, Egypt
Study Officials
- PRINCIPAL INVESTIGATOR
doaa DR rezk, master
University Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doaa011180@med.aun.edu.eg
Study Record Dates
First Submitted
October 1, 2021
First Posted
October 12, 2021
Study Start
October 1, 2021
Primary Completion
February 20, 2022
Study Completion
March 20, 2022
Last Updated
October 12, 2021
Record last verified: 2021-10